NCT06405139View on ClinicalTrials.gov

Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2027

Conditions
Colorectal Cancer
Interventions
DRUG

Nanoliposomal Irinotecan, Oxaliplatin plus Capecitabine

Nanoliposomal irinotecan 60mg/m2; Oxaliplatin 85 mg/m2; Capecitabine 800 mg/m2 twice daily, day 1 to 7; repeated every two weeks.

Trial Locations (1)

Unknown

RECRUITING

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER